Figure 2.

Overexpression of Nkx6.1 results in binding to the AURKA promoter in primary rat islets. Rat islets were treated with AdCMV-GFP or AdCMV-Nkx6.1. (A) Binding of Nkx6.1 to the promoter of MyoD, Insulin1 (negative controls), Cyclin A2 (positive control) and AURKA were measured by chromatin immunoprecipitation, using IgG or anti-Nkx6.1 antibody as the IP antibody. Data represent the mean ± SEM of 4 independent experiments. **P ≤ 0.01; ***P ≤ 0.001. P value represents the comparison between Nkx6.1- and GFP-treated islets.